Aspirin as a Therapeutic Agent in Cardiovascular Disease A Statement for Healthcare Professionals From the American Heart Association

摘要: Cardiovascular disease, which includes myocardial infarction, stroke, and peripheral vascular diseases, is the leading cause of death in United States most developed countries, accounting for more than 900 000 deaths annually alone. Aspirin can reduce risks occlusive events by inhibiting platelet aggregation,1 but uncertainty among healthcare providers remains regarding its appropriate use different categories patients. This concise review current knowledge, an update earlier AHA statement,2 intended to provide clinicians with guidelines aspirin treatment prevention cardiovascular disease. Aspirin therapy confers conclusive net benefits acute phase evolving infarction (MI) should be administered routinely virtually all patients MI. In Second International Study Infarct Survival (ISIS-2),3 17 men women within 24 hours onset symptoms suspected MI were randomly assigned 162 mg or placebo daily 30 days. After 5 weeks allocated receive had statistically significant reductions risk mortality (23%), nonfatal reinfarction (49%), stroke (46%). There was no increase hemorrhagic gastrointestinal bleeding treated group only a small minor bleeding. Thus, has perhaps best benefit-to-risk ratio any proven The on subsequent MI, are substantial serious sensitivity reactions low as well amenable care setting, even history other aspirin. contraindications relative, not absolute. To achieve immediate clinical antithrombotic effect, initial …